Page 2 - Primary Analysis News Today

In main results from the phase 3 trial, as well as those from an open-label extension, the investigational drug also proved its ability to positively influence several noninvasive efficacy outcomes.

The positive opinion is based on Phase 3 GLOW and Phase 2 CAPTIVATE study results, which investigated the efficacy and safety of ibrutinib plus venetoclax in patients with previously untreated CLL1

MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical

/PRNewswire/ -- Novartis announced Kymriah® (tisagenlecleucel) demonstrated strong efficacy in high-risk patients with relapsed or refractory (r/r) follicular...

Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant unmet need1 ...

/PRNewswire/ -- Four studies being presented during the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition point to the transformative...

Updated results from the MRD cohort of the Phase 2 CAPTIVATE study also highlight potential for treatment-free remissions with IMBRUVICA® plus venetoclax in an oral presentation at ASH... | December 11, 2021

/PRNewswire/ -- Four studies being presented during the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition point to the transformative...

Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant unmet need1 Median follow-up of approximately 17 months

/PRNewswire/ -- Novartis announced Kymriah® (tisagenlecleucel) demonstrated strong efficacy in high-risk patients with relapsed or refractory (r/r) follicular...